NeurogesX, Inc. (NGSX) Names Ronald Martell President and Chief Executive Officer

January 3, 2012 10:05 AM EST
NeurogesX, Inc. (Nasdaq: NGSX) today announced that the Board of Directors has appointed Ronald A. Martell as President and Chief Executive Officer, and a member of the board. Mr. Martell brings over 30 years of experience in the biotechnology industry including direct commercialization experience.

Prior to joining NeurogesX, Mr. Martell was Chief Executive Officer at Poniard Pharmaceuticals, Inc., where he served for four years. Mr. Martell's experience includes Imclone Systems, where over his tenure he held progressively more responsible positions, and led the successful launch and initial commercialization of oncology drug Erbitux and served as a member of the deal execution teams that led to major pharmaceutical partnerships. Earlier in his career, Mr. Martell was with Genentech and led the commercial launch of the company's blockbuster oncology drugs, Rituxan and Herceptin, as well as the development of global marketing plans for the oncology product portfolio.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Management Changes